---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; CAMZYOS"
date: 2026-02-04 21:49:09 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-16273
original_published: 2025-08-26 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; CAMZYOS

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** August 26, 2025 00:00 UTC
**Document Number:** 2025-16273

## Summary

The Food and Drug Administration (FDA or the Agency) published a notice in the Federal Register of February 29, 2024. After review of the calculation of the applicable regulatory review period of the biologic product CAMZYOS (U.S. patent numbers 9,181,200; 9,585,883) in that notice, FDA has determined that a revision of the supplementary information section is warranted. This notice corrects the applicable regulatory review period language.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/08/26/2025-16273/determination-of-regulatory-review-period-for-purposes-of-patent-extension-camzyos)
- API: https://www.federalregister.gov/api/v1/documents/2025-16273

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
